HALOZYME THERAPEUTICS INC. said FDA has accepted Genentech’s Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer indications. This is a co-formulation with Halozyme’s proprietary recombinant human hyaluronidase enzyme (ENHANZE platform), approved and marketed under the MabThera SC brand in countries outside the U.S. Halozyme Therapeutics is a biotechnology company focused...
The American Cancer Society’s 2026 annual statistics report trumpets a symbolic milestone for oncology—for the first time, the five-year relative survival rate for all cancers combined has reached 70% for people diagnosed between 2015 and 2021 in the U.S.
